GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Peptron Inc (XKRX:087010) » Definitions » Net Issuance of Preferred Stock

Peptron (XKRX:087010) Net Issuance of Preferred Stock : ₩0 Mil (TTM As of Jun. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Peptron Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Peptron's net issuance of preferred for the three months ended in Jun. 2024 was ₩0 Mil. The number is 0, which means that Peptron has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Peptron's net issuance of preferred for the trailing twelve months (TTM) ended in Jun. 2024 was ₩0 Mil.


Peptron Net Issuance of Preferred Stock Historical Data

The historical data trend for Peptron's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Peptron Net Issuance of Preferred Stock Chart

Peptron Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Issuance of Preferred Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Peptron Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Net Issuance of Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Peptron Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Peptron Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Peptron's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Peptron Business Description

Industry
Traded in Other Exchanges
N/A
Address
37-24, Yuseong-daero 1628 beon-gil, Yuseong-gu, Daejeon, KOR, 305811
Peptron Inc is a biotechnology company engaged in developing fundamental technologies for peptide-based medicines. Its technology includes PeptrEX and SmartDepot. PeptrEX is an automatic system, enabling to synthesize simultaneously from a few to hundred types of peptides. SmartDepot is a proprietary ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of the drug. The group's research and development products include Luphere Depot for the treatment of prostate cancer and endometriosis, SR Exenatide PT302 AND SR EXENATIDE PT304 for the treatment of type II diabetes, SR Exenatide PT320 and 330 for the treatment of Parkinson's and Alzheimer's disease and SR Octreotide for the treatment of acromegaly and carcinoid tumor.

Peptron Headlines

No Headlines